Table 3.

Hazard ratios for HIV-positive and HIV-negative Senegalese womena

Transition health stage
Initial health stageTotalnHR (95% CI)PnHR (95% CI)P
HPVHSIL
Normal107951228
 HIV+5092981.58 (1.32–1.89)<0.0001171.53 (0.73–3.21)0.26
 HIV570214ref.11ref.
 Incident classification6072981.58 (1.33–1.88)<0.0001181.69 (0.79–3.61)0.17
 Prevalent classification472214ref.10ref.
NormalHSIL
HPV1265764126
 HIV+6343080.46 (0.39–0.54)<0.0001872.55 (1.69–3.86)<0.0001
 HIV631456ref.39ref.
 Incident classification4993271.87 (1.60–2.18)<0.0001510.87 (0.60–1.25)0.44
 Prevalent classification766437ref.75ref.
NormalHPV
HSIL17925118
 HIV+117140.57 (0.26–1.29)0.18811.06 (0.71–1.59)0.77
 HIV6211ref.37ref.
 Incident classification109171.57 (0.70–3.49)0.27711.02 (0.71–1.48)0.91
 Prevalent classification708ref.47ref.
  • Abbreviations: Normal, HPV-negative; HPV, HPV-positive with one or more type in the absence of HSIL; HSIL, HPV-positive with one or more type with the presence of HSIL; Incident, stage differed from the preceding visit; Prevalent, baseline visit or stage was the same as the preceding visit.

  • aTransition numbers (by row) do not sum to the total provided as women remained in the same state for the duration of follow-up or transitioned to cervical cancer. Transitions to cancer were not examined due to extremely limited sample sizes.